EP Patent

EP4265261A2 — Methods and compositions for inhibiting expression of ldha

Assigned to Novo Nordisk Health Care AG · Expires 2023-10-25 · 3y expired

What this patent protects

This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.

USPTO Abstract

This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.

Drugs covered by this patent

Patent Metadata

Patent number
EP4265261A2
Jurisdiction
EP
Classification
—
Expires
2023-10-25
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk Health Care AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.